BMX-001 plus paclitaxel for advanced ovarian or endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether adding BMX-001 to the chemotherapy drug paclitaxel can help people with advanced ovarian or endometrial cancer that has come back or spread. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced, recurrent, or metastatic ovarian or endometrial cancer that got worse during or after standard treatment.
- You are at least 18 years old.
- You are in reasonably good health, able to care for yourself (ECOG score 0 or 1).
- You have tumors that can be measured or assessed by scans or fluid buildup.
- You are not pregnant and agree to use effective birth control if you could become pregnant.
- Your kidney, liver, and bone marrow function are adequate as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a weekly dose of the chemotherapy drug paclitaxel to standard treatment helps women with advanced or recurrent endometrial cancer. It is for patients whose cancer has returned or not responded to prior therapy, including at least one platinum-based chemotherapy and an immune checkpoint inhibitor.
This study tests a new drug (B013) combined with a standard chemotherapy (paclitaxel) for people with ovarian cancer that has come back after platinum-based treatment. The goal is to see if the combination works better than the current options.
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This trial tests a new targeted therapy called DT2216 combined with the chemotherapy paclitaxel for people with ovarian cancer that is resistant to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.